http://www.fpnotebook.com/

Ibutilide

Aka: Ibutilide, Corvert

Indications: Atrial Fibrillation Cardioversion
1. Time to Cardioversion: 1 hour
2. Conversion Rate: 33-45% (60% in Atrial Flutter)
Mechanism
1. Class III Antiarrhythmic
Dose
1. Initial
  1. Under 60 kg: 0.01 mg/kg IV over 10 min
  2. Over 60 kg: 1 mg IV over 10 min
2. Subsequent
  1. May repeat once after 10 min if not converted
Adverse Effects
1. Observe QT Interval
2. Evaluate Serum Potassium and Magnesium
3. Significantly proarrhythmic
  1. Ventricular Tachycardia or fibrillation risk: 1-2%
  2. Requires EKG monitoring for 4 hours after dose
Precautions
1. Most expensive Antiarrhythmic
2. Cardiac monitor on starting agent
  1. Continue for minimum of 4 hours
  2. Continue until QT Interval normalizes

ibutilide (C0082966)
Concepts	Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH	C067192
SnomedCT	108491000, 372500009
English	ibutilide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide, IBUTILIDE, ibutilide [Chemical/Ingredient], Ibutilide (product), Ibutilide (substance), Ibutilide
Spanish	ibutilida (producto), ibutilida (sustancia), ibutilida
Sources	Derived from the NIH UMLS (Unified Medical Language System)

Corvert (C0644117)
Concepts	Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH	C067192
English	Pfizer brand of ibutilide fumarate, Corvert
Sources	Derived from the NIH UMLS (Unified Medical Language System)

Family Practice Notebook

Patients should address specific medical concerns with their physicians.

Although access to this page is not restricted, the information found here is intended for use by medical providers.

This page was written by Scott Moses, MD, last revised on 10/21/2007 and last published on 5/14/2013.

This is one of 5887 pages in the Family Practice Notebook